DailyMed Label: Bromfenac Ophthalmic Solution, 0.07%

DailyMed Label: Bromfenac Ophthalmic Solution, 0.07%

2017

DailyMed Prescription

Bromfenac Ophthalmic Solution, 0.07%

Bromfenac Sodium

Apotex Corp.

NDC: 60505-1006

NDC: 60505-1006

NDC: 60505-1006

NDC: 60505-1006

Bromfenac Ophthalmic Solution, 0.07% is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Each mL of Bromfenac Ophthalmic Solution, 0.07% contains 0.805 mg bromfenac sodium sesquihydrate (equivalent to 0.7 mg bromfenac free acid). The USAN name for bromfenac sodium sesquihydrate is bromfenac sodium. Bromfenac sodium is designated chemically as sodium [2-amino-3-(4-bromobenzoyl) phenyl] acetate sesquihydrate, with an empirical formula of C 15 H 11 BrNNaO 3 • 1½ H 2 O. The chemical structure for bromfenac sodium sesquihydrate is: Bromfenac sodium is a yellow or orange crystalline powder. The molecular weight of bromfenac sodium is 383.17. Bromfenac Ophthalmic Solution, 0.07% is supplied as a sterile aqueous 0.07% solution, with a pH of 7.8. The osmolality of Bromfenac Ophthalmic Solution, 0.07% is approximately 300 mOsmol/kg. Each mL of Bromfenac Ophthalmic Solution, 0.07% contains:   Active : Each mL contains bromfenac sodium sesquihydrate 0.0805%, which is equivalent to bromfenac free acid 0.07%. Preservative : benzalkonium chloride 0.005% Inactives : boric acid, edetate disodium dihydrate, povidone, sodium borate, sodium sulfite anhydrous, tyloxapol, sodium hydroxide to adjust pH and water for injection. Chemical-Structure

Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Bromfenac Ophthalmic Solution, 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. ( 1 )

Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery, and through the first 14 days post-surgery. ( 2.1 ) One drop of bromfenac ophthalmic solution, 0.07% should be applied to the affected eye once daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the postoperative period. Bromfenac ophthalmic solution, 0.07% may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.

Topical ophthalmic solution: bromfenac 0.07% Topical ophthalmic solution: bromfenac 0.07% ( 3 )

None None ( 4 )

• Sulfite Allergic Reactions ( 5.1 ) • Slow or Delayed Healing ( 5.2 ) • Potential for cross-sensitivity ( 5.3 ) • Increase bleeding of ocular tissues ( 5.4 ) • Corneal effects including keratitis ( 5.5 ) • Contact Lens Wear ( 5.6 ) Contains sodium sulfite, a sulfite that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people. All topical nonsteroidal anti-inflammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs. With some NSAIDs, including bromfenac, there exists the potential for increased bleeding time due to interference with platelet aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. It is recommended that bromfenac ophthalmic solution, 0.07% be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health. Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events. Bromfenac ophthalmic solution, 0.07% should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of bromfenac ophthalmic solution, 0.07%. The preservative in bromfenac ophthalmic solution, 0.07%, benzalkonium chloride may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of bromfenac ophthalmic solution, 0.07%.

The most commonly reported adverse reactions in 3 to 8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and vision blurred. (

Treatment of rats at oral doses up to 0.9 mg/kg/day (systemic exposure 90 times the systemic exposure predicted from the recommended human ophthalmic dose [RHOD] assuming the human systemic concentration is at the limit of quantification) and rabbits at oral doses up to 7.5 mg/kg/day (150 times the predicted human systemic exposure) produced no treatment-related malformations in reproduction studies. However, embryo-fetal lethality and maternal toxicity were produced in rats and rabbits at 0.9 mg/kg/day and 7.5 mg/kg/day, respectively. In rats, bromfenac treatment caused delayed parturition at 0.3 mg/kg/day (30 times the predicted human exposure), and caused dystocia, increased neonatal mortality and reduced postnatal growth at 0.9 mg/kg/day. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of bromfenac ophthalmic solution, 0.07% during late pregnancy should be avoided. Caution should be exercised when bromfenac ophthalmic solution, 0.07% is administered to a nursing woman. Safety and efficacy in pediatric patients below the age of 18 years have not been established. There is no evidence that the efficacy or safety profiles for bromfenac ophthalmic solution, 0.07% differ in patients 70 years of age and older compared to younger adult patients.

Bromfenac Ophthalmic Solution, 0.07% is supplied in a white opaque LDPE plastic bottle with a white translucent LDPE dropper and gray opaque HDPE plastic cap as follows: • 1.6 mL in a 5 mL container (NDC 60505-1006-1) • 3 mL in a 5 mL container (NDC 60505-1006-2) Storage: Store at 20º to 25ºC (68º to 77ºF) [See USP Controlled Room Temperature].

Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase (COX) 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure. The plasma concentration of bromfenac following ocular administration of 0.07% bromfenac ophthalmic solution in humans is unknown. Based on the maximum proposed dose of one drop to each eye (0.035 mg) and PK information from other routes of administration, the systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans.

Long-term carcinogenicity studies in rats and mice given oral doses of bromfenac up to 0.6 mg/kg/day (systemic exposure 30 times the systemic exposure predicted from the recommended human ophthalmic dose [RHOD] assuming the human systemic concentration is at the limit of quantification) and 5 mg/kg/day (340 times the predicted human systemic exposure), respectively, revealed no significant increases in tumor incidence. Bromfenac did not show mutagenic potential in various mutagenicity studies, including the reverse mutation, chromosomal aberration, and micronucleus tests. Bromfenac did not impair fertility when administered orally to male and female rats at doses up to 0.9 mg/kg/day and 0.3 mg/kg/day, respectively (systemic exposure 90 and 30 times the predicted human exposure, respectively).

Bromfenac 0.07% QD for the treatment of postoperative inflammation and reduction of ocular pain was evaluated in two multi-center, randomized, double-masked, parallel-group and placebo (vehicle)-controlled studies. Patients undergoing cataract surgery self-administered bromfenac 0.07% or vehicle once daily, beginning 1 day prior to surgery, continuing on the morning of surgery and for 14 days after surgery.  Complete clearance of ocular inflammation (0 cell and no flare) was assessed on Days 1, 3, 8 and 15 post-surgery using slit lamp biomicroscopy. The pain score was self-reported. The primary efficacy endpoint was the proportion of subjects who had complete clearance of ocular inflammation by day 15. In the intent-to-treat analyses from both assessments, complete clearance at Day 8 and Day 15, bromfenac 0.07% was superior to vehicle as shown in the following table. Proportion of Subjects with Cleared Ocular Inflammation (0 cells and no flare) Study Visit Bromfenac 0.07% Vehicle Difference (%) (Asymptotic 95% CI) Study 1 At Day 8 27/112 (24.1%) 7/108 (6.5%) 17.6 (8.4, 26.8) At Day 15 51/112 (45.5%) 14/108 (13.0%) 32.5 (21.4, 43.8) Study 2 At Day 8 33/110 (30.0%) 14/110 (12.7%) 17.3 (6.7, 27.9) At Day 15 50/110 (45.5%) 30/110 (27.3%) 18.2 (5.7, 30.7) Proportion of Subjects who Were Pain Free Study Visit Bromfenac 0.07% Vehicle Difference (%) (Asymptotic 95% CI) Study 1 At Day 1 91/112 (81.3%) 47/108 (43.5%) 37.7 (25.9, 49.6) Study 2 At Day 1 84/110 (76.4%) 61/110 (55.5%) 20.9 (8.7, 33.1)

NDC 60505-1006-2 Bromfenac Ophthalmic Solution, 0.07% Sterile Rx only 3 mL Once Daily